glp-1 bmi requirements Are you in the red zone? 🚨 Most people don't realize they actually qualify for medications like Zepbound under standard insurance guidelines. ​Here is the official criteria: 🔴 of 30 GLP-1 Eligibility Explained: BMI Cutoffs

Women with PMOS show chronically elevated pro-inflammatory cytokines particularly TNF-, IL-6, and CRP independent of obesity

Ludvik B et al

Patients managing multiple chronic conditions, those on medications affecting absorption, or individuals with biomarker profiles suggesting heightened peptide pathway activity should prioritize consistent, non-degraded formulations

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

Baseline Labs advantages